Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspira Women's Health Inc. (AWHL) SEC filings page on Stock Titan brings together the company’s official regulatory documents, offering a detailed view of its operations, capital structure, and risk profile. Aspira is a smaller reporting company in the diagnostics and research segment of healthcare, focused on noninvasive, AI-powered tests for gynecologic diseases such as ovarian cancer and endometriosis.
Through registration statements on Form S-1 and S-1/A, Aspira outlines its business model, including its OvaSuite℠ portfolio of ovarian cancer risk assessment tests (OvaWatch® and Ova1Plus®), its CLIA laboratory operations, and its development pipeline for the ENDOinform™ endometriosis test. These filings also describe the company’s plans to commercialize its technology, its use of multi-omics biomarkers and AI algorithms, and its status as a non-accelerated filer and smaller reporting company.
Investors can review Form 8-K current reports for material events such as private placements of convertible notes and warrants, equity purchase agreements, laboratory services agreements, listing changes from OTCQB to OTCQX, and updates on government-funded programs. Filings detailing purchase agreements with institutional investors and equity line arrangements provide insight into how Aspira raises capital to support its commercial and R&D activities.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that help explain complex sections of Aspira’s filings. Users can quickly understand key elements of annual and quarterly reports when available, including product revenue composition, operating expense trends, and liquidity discussions, as disclosed in the company’s financial statements. Form 4 insider transaction reports, when filed, can be accessed to see how directors and officers transact in AWHL shares.
Use this SEC filings hub to navigate Aspira’s S-1 and S-1/A registration statements, 8-K and 8-K/A current reports, and other disclosures. The AI-generated overviews are designed to highlight important terms, financing structures, and business descriptions so that readers can more efficiently interpret Aspira Women’s Health Inc.’s regulatory record.
Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons. Strahley will work in a fractional role, committing at least twenty hours per week.
Under his Executive Employment Agreement, Strahley receives an annualized base salary of $167,000 and is eligible for the company’s 401(k) plan but not for group insurance benefits. The Board will approve stock options for 70,000 shares at fair market value on the grant date, with 25% vesting ninety days after his start date and the remainder vesting monthly over the following nine months. Any unvested options fully vest upon a Change in Control, and his at-will employment includes no severance beyond accrued obligations.
Aspira Women’s Health Inc. is asking stockholders to vote at its June 17, 2026 annual meeting in Houston on four main items. Stockholders will elect six directors for one-year terms, hold an advisory "say-on-pay" vote on executive compensation, and consider an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, increasing the total authorized under the plan to 9,532,818 shares and raising the cap on incentive stock options to 15,000,000 shares. They will also vote on ratifying BDO USA, P.C. as independent auditor for 2026. The record date is April 20, 2026, when 43,500,411 common shares were outstanding. The proxy describes board structure, committee work, director and executive pay, and change-in-control severance protections.
Aspira Women’s Health Inc. reports that there is substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $544.177 million and insufficient capital to fund operations through 2026. The company is pursuing strategic alternatives and new financing after converting $1.365 million of senior secured convertible notes into equity units in March 2025. Aspira lost a key non-dilutive funding source when its ENDOinform contract with ARPA-H was terminated after paying $2.0 million in late 2024 and $1.5 million in early 2025, which may delay commercialization of its endometriosis test. Its shares were delisted from Nasdaq in April 2025 for failing listing standards and now trade on the OTC QX Market under the symbol AWHL. The business remains focused on AI-powered gynecologic diagnostics, including Ova1Plus and OvaWatch, with 22,515 OvaSuite tests performed in 2025 and Medicare reimbursement for Ova1 and OvaWatch at $897 per test.
Aspira Women’s Health Inc. notified the SEC it could not timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company states it needs additional time to complete accounting and disclosures related to its tax provision for the year ended December 31, 2025 and expects to file the Form 10-K within the 15 calendar day extension period. The notification is dated April 1, 2026 and lists Brian Hungerford, CFO as the contact.
Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories. The agreement is effective as of December 16, 2025 and had previously been disclosed as a material definitive agreement.
The amendment mainly adds the agreement as Exhibit 10.1 after completing redactions of private or confidential information. No financial results or other business updates are included beyond this contract filing.
Aspira Women’s Health Inc. entered into a new subordinated secured term loan agreement with Agile Lending, LLC and other lenders. The company issued a subordinated secured promissory note with $1,050,000 principal and total interest charges of $441,000 (assuming timely payments), maturing on August 26, 2026. The loan is subordinated to all senior indebtedness and is secured by a continuing security interest in substantially all personal property of the company and certain subsidiary co-borrowers, subject to customary exclusions. Proceeds will be used for general corporate purposes, and the agreement contains customary covenants and events of default that allow lenders to accelerate obligations and enforce on collateral if triggered.
Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity financing arrangement. The registered shares include up to 15,873,016 shares that Aspira may sell to Lincoln Park over 24 months under a $10.0 million purchase agreement, plus 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but can raise up to $10.0 million in gross proceeds from its own future sales of purchase shares to Lincoln Park, at prices tied to the market price of its stock. The company highlights potential dilution and stock price pressure from these issuances and resales, notes that its stock trades on the OTCQX under the symbol AWHL, and describes significant trading volatility and governance provisions that may affect control and liquidity.
Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity purchase arrangement.
The registered shares include up to 15,873,016 shares Aspira may sell to Lincoln Park over 24 months and 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but may raise up to $10.0 million in gross proceeds from its own sales of purchase shares to Lincoln Park, with pricing based on future market prices.
Aspira had 43,480,411 common shares outstanding as of December 29, 2025, including the commitment shares, and estimates 59,353,427 shares would be outstanding if all purchase shares are issued. The stock trades on the OTCQX under the symbol AWHL, where it closed at $0.63 on December 29, 2025.